Viridian Announces Positive Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients With Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune system attacks the tissues around and behind the eyes causing inflammation, swelling, and damage that develops into debilitating signs and symptoms including double vision, bulging eyes, and ocular pain.

“These additional Phase 1/2 clinical data continue to support the potential for VRDN-001 to be a new treatment option for patients suffering from TED,” said Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center and an investigator on the VRDN-001 trial.

Share

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder